Conejo-Mir J, Conejo-Mir L

Idioma: Español
Referencias bibliográficas: 19
Paginas: 105-108
Archivo PDF: 66.87 Kb.

FRAGMENTO

Hasta los años 80, los tratamientos utilizados en carcinomas basocelulares (CB) y espinocelulares (CE) eran comunes. La cirugía se mostraba como mejor opción, seguida muy a distancia de otros tratamientos, como la criocirugía y electrocirugía, de efectos más paliativos que curativos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Greenway HT. Interferon. West J Med 1994;160:363.

2. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41:1002-7.

3. Quinn AG, Epstein E Jr. Patched, hedgehog, and skin cancer. Methods Mol Biol 2003; 222: 85-95.

4. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signaling in skin development and cancer. Exp Dermatol 2006;15: 667-77.

5. Eichberger T, Regl G, Ikram MS, Neill GW, Philpott MP, Aberger F, Frischauf AM. FOXE1, a new transcriptional target of GLI2is expressed in human epidermis and basal cell carcinoma. J Invest Dermatol 2004; 122: 1180-7.

6. Ling G, Ahmadian A, Persson A, Undén AB, Afink G, Williams C et al. PATCHED and p53 gene alterations in sporadic and hereditarybasal cell cancer. Oncogene 2001; 20: 7770-8.

7. Couvé-Privat S, Bouadjar B, Avril MF, Sarasin A, Daya-Grosjean L. Significantly high levels of ultraviolet-specific mutations in the SMOothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res 2002; 62: 7186-9.

8. Rubin L, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Disc 2006; 5: 1026-33.

9. Stanton BZ, Peng LF. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst 2010; 6: 44-54.

10. Incardona JP, Gaffield W, Kapur RP, Roelink H. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development 1998; 125: 3553-62.

11. Athar M, Li C, Tang X, Chi S, Chi S, Zhang X, Kim AL et al. Inhibition of Smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res 2004; 64: 7545-52.

12. Tremblay MR, Lescarbeau A, Grogan MJ, Tan E, Lin G, Austad BC et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009; 52: 4400-18.

13. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361: 1164-72.

14. De Smaele E, Ferretti E, Gulino A. ViSMOdegib, a small-mollecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010; 11: 707-18.

15. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411: 349-54.

16. Cooper MK, Wassif CA, Krakowiak PA, Taipale J, Gong R, Kelley RI, Porter FD, Beachy PA. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 2003;33:508-13. Erratum in: Nat Genet 2003; 34: 113.

17. Dellavalle RP, Drake A, Graber M, Heilig LF, Hester EJ, Johnson KR, McNealy K, Schilling L. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev 2005: CD003697.

18. Brüggemann LW, Queiroz KC, Zamani K, van Straaten A, Spek CA, Bijlsma MF. Assessing the efficacy of the Hedgehog pathway inhibitor vitamin D3 in a murine xenograft model for pancreatic cancer. Cancer Biol Ther 2010; 10.

19. Schnidar H, Eberl M, Klingler S, Mangelberger D, Kasper M, Hauser-Kronberger C et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009; 69: 1284-92.